vildagliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dipeptidyl aminopeptidase-IV inhibitors 3642 274901-16-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • xiliarx
  • galvus
  • vildagliptin
  • jalra
  • NVP-LAF237
  • vildagliptin hydrochloride
  • vildagliptin HCl
A pyrrolidine-carbonitrile derivative and potent inhibitor of DIPEPTIDYL PEPTIDASE 4 that is used in the treatment of TYPE 2 DIABETES MELLITUS.
  • Molecular weight: 303.41
  • Formula: C17H25N3O2
  • CLOGP: 0.97
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 76.36
  • ALOGS: -2.24
  • ROTB: 3

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.03 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.89 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.67 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 26, 2007 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 1032.04 24.23 202 3754 5705 50595463
Lactic acidosis 225.20 24.23 88 3868 33267 50567901
Acute kidney injury 126.04 24.23 119 3837 227939 50373229
Hypoglycaemia 98.99 24.23 58 3898 53523 50547645
Diabetes mellitus inadequate control 68.99 24.23 29 3927 13116 50588052
Dermatitis bullous 59.35 24.23 22 3934 7151 50594017
Crush syndrome 59.02 24.23 10 3946 119 50601049
Sensorimotor disorder 52.40 24.23 11 3945 433 50600735
Compartment syndrome 49.23 24.23 14 3942 1968 50599200
Glycosylated haemoglobin increased 44.54 24.23 20 3936 10586 50590582
Hyperkalaemia 42.55 24.23 33 3923 48056 50553112
Acute generalised exanthematous pustulosis 41.22 24.23 18 3938 8920 50592248
Shock 39.77 24.23 23 3933 20627 50580541
Hyperglycaemia 38.94 24.23 28 3928 36377 50564791
Language disorder 37.18 24.23 11 3945 1777 50599391
Polymyalgia rheumatica 37.00 24.23 12 3944 2624 50598544
Blood glucose increased 36.84 24.23 36 3920 71288 50529880
Hyperphosphataemia 36.68 24.23 11 3945 1860 50599308
Capillary leak syndrome 36.57 24.23 11 3945 1879 50599289
Altered state of consciousness 35.93 24.23 22 3934 21888 50579280
Hyperparathyroidism secondary 35.63 24.23 10 3946 1340 50599828
Drug interaction 35.31 24.23 59 3897 199562 50401606
Rhabdomyolysis 34.99 24.23 27 3929 39000 50562168
Hypomagnesaemia 34.81 24.23 22 3934 23134 50578034
Eosinophilia 33.87 24.23 20 3936 18632 50582536
Hypoparathyroidism 33.25 24.23 8 3948 586 50600582
Blood phosphorus increased 33.20 24.23 11 3945 2571 50598597
Renal impairment 31.48 24.23 34 3922 75627 50525541
Cerebral infarction 31.17 24.23 20 3936 21584 50579584
Bladder sphincter atony 30.87 24.23 6 3950 159 50601009
Diabetic ketoacidosis 29.44 24.23 18 3938 17854 50583314
Acetonaemia 27.73 24.23 5 3951 87 50601081
Urine ketone body present 26.28 24.23 9 3947 2324 50598844
Drug reaction with eosinophilia and systemic symptoms 26.21 24.23 20 3936 28404 50572764
Thrombocytosis 26.12 24.23 11 3945 4985 50596183
Diabetic metabolic decompensation 26.01 24.23 8 3948 1472 50599696
Cutaneous lupus erythematosus 25.92 24.23 9 3947 2422 50598746
Overdose 25.45 24.23 35 3921 99692 50501476
Ketoacidosis 25.23 24.23 10 3946 3885 50597283

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 885.52 21.74 212 4589 7369 29562357
Diabetes mellitus inadequate control 79.55 21.74 39 4762 12095 29557631
Cardiac failure 58.38 21.74 68 4733 79219 29490507
Hypoglycaemia 58.22 21.74 54 4747 48292 29521434
Euglycaemic diabetic ketoacidosis 49.81 21.74 18 4783 2612 29567114
Cerebral infarction 49.38 21.74 37 4764 24638 29545088
Hyperglycaemia 46.57 21.74 41 4760 34246 29535480
Ketonuria 41.47 21.74 11 4790 569 29569157
Acute kidney injury 37.65 21.74 111 4690 265156 29304570
Diabetic ketoacidosis 34.16 21.74 25 4776 16048 29553678
Glycosylated haemoglobin increased 30.42 21.74 19 4782 9407 29560319
Interstitial lung disease 28.99 21.74 41 4760 57677 29512049
Bone marrow oedema 28.86 21.74 8 4793 489 29569237
Orbital oedema 27.19 21.74 6 4795 141 29569585
Drug interaction 26.41 21.74 81 4720 197304 29372422
Hyperkalaemia 25.65 21.74 40 4761 61352 29508374
Intercepted medication error 24.69 21.74 7 4794 465 29569261
Blister 23.47 21.74 22 4779 19884 29549842
Nervous system disorder 23.12 21.74 18 4783 12656 29557070
Acetonaemia 21.75 21.74 5 4796 142 29569584

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 1828.02 18.86 409 8391 12577 64477355
Lactic acidosis 177.04 18.86 108 8692 61302 64428630
Acute kidney injury 141.13 18.86 233 8567 449007 64040925
Hypoglycaemia 139.73 18.86 108 8692 89784 64400148
Diabetes mellitus inadequate control 112.69 18.86 56 8744 21265 64468667
Hyperglycaemia 81.29 18.86 67 8733 60901 64429031
Cerebral infarction 76.39 18.86 55 8745 40989 64448943
Hyperkalaemia 69.41 18.86 77 8723 101052 64388880
Dermatitis bullous 64.68 18.86 32 8768 12022 64477910
Euglycaemic diabetic ketoacidosis 60.33 18.86 24 8776 5386 64484546
Diabetic ketoacidosis 60.16 18.86 42 8758 29803 64460129
Drug interaction 53.62 18.86 138 8662 361945 64127987
Altered state of consciousness 51.22 18.86 42 8758 37860 64452072
Eosinophilia 51.05 18.86 42 8758 38034 64451898
Crush syndrome 49.58 18.86 10 8790 180 64489752
Glycosylated haemoglobin increased 48.20 18.86 29 8771 15990 64473942
Renal impairment 46.11 18.86 73 8727 134944 64354988
Acetonaemia 45.97 18.86 10 8790 263 64489669
Interstitial lung disease 45.22 18.86 61 8739 97671 64392261
Polymyalgia rheumatica 41.32 18.86 16 8784 3343 64486589
Ketonuria 40.55 18.86 12 8788 1105 64488827
Cardiac failure 40.36 18.86 68 8732 132305 64357627
Sensorimotor disorder 39.95 18.86 11 8789 782 64489150
Toxicity to various agents 38.30 18.86 3 8797 363510 64126422
Fatigue 36.95 18.86 29 8771 748701 63741231
Blister rupture 35.03 18.86 9 8791 490 64489442
Urine ketone body present 34.55 18.86 14 8786 3293 64486639
Hypomagnesaemia 33.77 18.86 33 8767 37343 64452589
Compartment syndrome 31.22 18.86 14 8786 4218 64485714
Bladder sphincter atony 29.70 18.86 6 8794 109 64489823
Headache 29.39 18.86 18 8782 529449 63960483
Rhabdomyolysis 29.11 18.86 48 8752 91678 64398254
Thrombocytosis 26.97 18.86 15 8785 7141 64482791
Language disorder 26.67 18.86 11 8789 2706 64487226
Diabetic metabolic decompensation 26.63 18.86 11 8789 2717 64487215
Cardiac failure acute 26.12 18.86 20 8780 16324 64473608
Hyperphosphataemia 25.69 18.86 12 8788 3969 64485963
Hypoparathyroidism 25.66 18.86 8 8792 879 64489053
Blood glucose increased 25.49 18.86 47 8753 98026 64391906
Ketoacidosis 24.81 18.86 14 8786 6849 64483083
Hyperparathyroidism secondary 24.81 18.86 10 8790 2320 64487612
Inflammatory marker increased 24.65 18.86 15 8785 8436 64481496
Capillary leak syndrome 24.62 18.86 11 8789 3286 64486646
Acute generalised exanthematous pustulosis 24.24 18.86 18 8782 14040 64475892
Orbital oedema 24.11 18.86 6 8794 287 64489645
Bone marrow oedema 23.61 18.86 8 8792 1142 64488790
Pain 23.03 18.86 25 8775 553486 63936446
Cholangitis acute 22.85 18.86 8 8792 1260 64488672
Shock 22.63 18.86 27 8773 38213 64451719
Shock haemorrhagic 21.41 18.86 18 8782 16773 64473159
Hypophosphataemia 21.33 18.86 17 8783 14703 64475229
Toxic skin eruption 21.21 18.86 19 8781 19265 64470667
Drug reaction with eosinophilia and systemic symptoms 20.85 18.86 31 8769 54186 64435746
Thyroglobulin increased 20.65 18.86 4 8796 58 64489874
Blood phosphorus increased 20.38 18.86 11 8789 4935 64484997
Erythema multiforme 20.37 18.86 17 8783 15684 64474248
Cutaneous lupus erythematosus 20.19 18.86 9 8791 2673 64487259
Neutrophilia 19.83 18.86 12 8788 6682 64483250
Joint swelling 19.58 18.86 3 8797 215379 64274553
Monoparesis 19.42 18.86 9 8791 2925 64487007
Anaemia 19.19 18.86 102 8698 378578 64111354
Glycosuria 19.02 18.86 8 8792 2066 64487866

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BH02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Dipeptidyl peptidase 4 (DPP-4) inhibitors
MeSH PA D054873 Dipeptidyl-Peptidase IV Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D011480 Protease Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Dipeptidyl peptidase 4 Enzyme INHIBITOR Ki 8.52 CHEMBL DRUG LABEL
Dipeptidyl peptidase 8 Enzyme Ki 6.09 CHEMBL
Dipeptidyl peptidase 9 Enzyme Ki 7.17 CHEMBL
Prolyl endopeptidase FAP Enzyme IC50 5.43 CHEMBL
Dipeptidyl peptidase 9 Unclassified IC50 6.17 CHEMBL
Dipeptidyl peptidase IV Unclassified Ki 7.77 CHEMBL
Prolyl endopeptidase FAP Enzyme IC50 4.28 CHEMBL

External reference:

IDSource
D07080 KEGG_DRUG
C1570906 UMLSCUI
CHEBI:135285 CHEBI
CHEMBL142703 ChEMBL_ID
DB04876 DRUGBANK_ID
D000077597 MESH_DESCRIPTOR_UI
6918537 PUBCHEM_CID
6310 IUPHAR_LIGAND_ID
8399 INN_ID
I6B4B2U96P UNII
596554 RXNORM
012358 NDDF
428611002 SNOMEDCT_US
428807006 SNOMEDCT_US
LF7 PDB_CHEM_ID

Pharmaceutical products:

None